Lichenoid Drug Eruption after Low-Dose Imatinib Mesylate Treatment
نویسندگان
چکیده
500 Ann Dermatol Received October 19, 2012, Revised December 1, 2012, Accepted for publication December 5, 2012 Corresponding author: Dong-Youn Lee, Department of Dermatology, Samsung Medical Center, 81 Irwon-ro, Gangnam-gu, Seoul 135-710, Korea. Tel: 82-2-3410-3543, Fax: 82-2-3410-3869, E-mail: dylee@ skku.edu This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http:// creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. sed in specific types of cancer, KAI1 is over expressed in MM. Interestingly, KAI1 was not expressed in cutaneous BCCs, SCCs and normal tissues. More work is needed to characterize the pathway through which KAI1 is overexpressed in MM skin tumor.
منابع مشابه
Lichenoid drug eruption with palmoplantar hyperkeratosis due to imatinib mesylate: a case report and a review of the literature.
Cutaneous adverse effects of imatinib mesylate (Glivec) are common and various types of skin eruptions have been reported. We report here a 57-year-old man who presented with lichen planus-like lesions on his extremities and palmoplantar hyperkeratosis due to the use of imatinib mesylate for chronic myeloid leukaemia. The skin lesions improved after discontinuation of imatinib mesylate but re-a...
متن کاملImatinib mesylate-induced lichenoid drug eruption.
Imatinib mesylate (imatinib) is a tyrosine kinase inhibitor initially approved by the US Food and Drug Administration in 2001 for chronic myeloid leukemia (CML). Since then, the number of indicated uses for imatinib has substantially increased. It is increasingly important that dermatologists recognize adverse cutaneous manifestations of imatinib and are aware of their management and outcomes t...
متن کاملCross Skin Reactivity to Tyrosine Kinase Inhibitors in a Patient with Chronic Myelogenous Leukemia
Tyrosine kinase inhibitors (TKI) targeting the bcr-abl protein, c-kit and the platelet-derived growth factor receptors, are significant part of the pathogenic therapy of chronic myelogenous leukemia. A broad spectrum of cutaneous side effects has been described with the clinical use of imatinib mesylate, ranging from various acute rashes to toxic epidermal necrolysis. Herein, a case of cross sk...
متن کاملMinor Salivary Gland Sialolithiasis of the Upper Lip
502 Ann Dermatol Received November 22, 2012, Accepted for publication December 5, 2012 Corresponding author: Bark-Lynn Lew, Department of Dermatology, Kyung Hee University Hospital at Gangdong, 892 Dongnam-ro, Gangdong-gu, Seoul 134-727, Korea. Tel: 82-2-440-7329, Fax: 82-2-4407336, E-mail: [email protected] This is an Open Access article distributed under the terms of the Creative Commons A...
متن کاملCutaneous lichenoid eruption caused by imatinib mesylate in a Japanese patient with chronic myeloid leukaemia.
© 2009 The Authors. doi: 10.2340/00015555-0636 Journal Compilation © 2009 Acta Dermato-Venereologica. ISSN 0001-5555 Sir, Chronic myeloid leukaemia (CMV) is a clonal myeloproliferative disorder, in which the Philadelphia chromosome is the cytogenetic hallmark. It is characterized by the t(9;22) translocation, which in turn creates the chimeric bcr-abl oncogene coding for a constitutively activa...
متن کامل